Adherence to somatostatin analog therapy for acromegaly

The main goals of treatment for many diseases are to improve the prognosis of diseases and to enhance the quality of life. Among the barriers that restrict achieving these goals we have to mention adherence to treatment. Patients with chronic diseases, including acromegaly, are at increased risk of poor adherence to treatment. The duration of supervision of patients with acromegaly in most cases exceeds 25-30 years, which makes the issue of adherence to treatment extremely important.

One of the main goals of the acromegaly treatment is to achieve the target values of STH and IGF-1, which ensures the regression of most clinical symptoms and restoration of life expectancy. For this purpose, a significant proportion of patients with acromegaly receive somatostatin analog treatment - as a second line of treatment after non-radical neurosurgical intervention, or as the first line of treatment if neurosurgical intervention could not be performed for any reason. Adherence to treatment is influenced by socio-economic factors, the characteristics of the drug, and the characteristics of the patient. Recent studies have shown that the easy administration of lanreotide provides better treatment adherence than octreotide. Factors that can reduce adherence to the treatment of acromegaly are old age, mental disorders, subjective opinion about the low quality of life, the need to visit medical institutions to administer the drug. On the contrary, the ability to perform subcutaneous injections (on their own or with the help of relatives) without visiting medical facilities, providing accessible information about the disease and the need for its treatment significantly increases adherence to treatment. It is necessary to continue research on the factors and methods of increasing adherence to drug treatment of acromegaly.

1. Lukina Yu.V., Kutishenko N.P., Martsevich S.Yu. Treatment adherence: modern view on a well-known issue. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2017;16(1):91-95. (In Russ.) doi: 10.15829/1728-8800-2017-1-91-95.

2. Truglio-Londrigan M., Slyer J.T., Singleton J.K., Worral P. A qualitative systematic review of internal and external influences on shared decision-making in all health care settings. JBI Libr Syst Rev. 2012;10(58):4633-4646. doi: 10.11124/jbisrir-2012-432.

3. Brown M.T., Bussell J., Dutta S., Davis K., Strong S., Mathew S. Medication Adherence: Truth and Consequences. Am J Med Sci. 2016;351(4):387-399. doi: 10.1016/j.amjms.2016.01.010.

4. Danilov D.S. Therapeutic collaboration (compliance): Content of the definition, mechanisms of formation, and methods of optimization. Nevrologiya, neyropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2014;(2):4-12. (In Russ.) doi: 10.14412/2074-2711-2014-2-4-12.

5. Van Dulmen S., Sluijs E., van Dijk L., de Ridder D., Heerdink R., Bensing J. Patient adherence to medical treatment: a review of reviews. BMC Health Serv Res. 2007;17(7):55. doi: 10.1186/1472-6963-7-55.

6. Leslie K.H., McCowan C., Pell J.P. Adherence to cardiovascular medication: a review of systematic reviews. J Public Health (Oxf). 2019;41(1):e84-e94. doi: 10.1093/pubmed/fdy088.

7. Nebieridze D.V., Kamyshova T.V., Safaryan A.S., Sargsyan V.D. Treatment adherence as an essential element of cardiovascular disorders management. Kardio-vaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2017;16(6):128-132. (In Russ.) doi: 10.15829/1728-8800-2017-6-128-132.

8. Schneider A.P.H., Gaedke M.A., Garcez A., Barcellos N.T., Paniz V.M.V. Effect of characteristics of pharmacotherapy on non-adherence in chronic cardiovascular disease: A systematic review and meta-analysis of observational studies. Int J Clin Pract. 2018;72(1):e13044. doi: 10.1111/ijcp.13044.

9. Chowdhury R., Khan H., Heydon E., Shroufi A., Fahimi S., Moore C. et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013;34(38):2940-2948. doi: 10.1093/eurheartj/eht295.

10. Krass I., Schieback P., Dhippayom T. Adherence to diabetes medication: a systematic review. Diabet Med. 2015;32(6):725-737. doi: 10.1111/dme.12651.

11. Hamedi-Shahraki S., Eshraghian M.R., Yekaninejad M.S., Nikoobakht M., Rasekhi A., Chen H., Pakpour A. Health-related quality of life and medication adherence in elderly patients with epilepsy. Neurol Neurochir Pol. 2019;53(2):123-130. doi: 10.5603/PJNNS.a2019.0008.

12. Morugova T.V., Abusuev S.A., Bazorkina A.A., Taova T.P., Bembeeva L.U., Temirdasheva N.M. et al. Acromegaly: clinic, diagnosis, differential diagnosis, treatment: clinical guidelines. Moscow; 2014. 37 p. (In Russ.) Available at: https://www.endocrincentr.ru/sites/default/files/specialists/science/clinic-recomendations/rec_acromegalia_2014.pdf.

13. Katznelson L., Laws E.R. Jr, Melmed S., Molitch M.E., Murad M.H., Utz A., Wass J.A. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(11):3933-3951. doi: 10.1210/jc.2014-2700

14. Colao A., Grasso L.F.S., Giustina A., Melmed S., Chanson P., Pereira A.M., Pivonello R. Acromegaly. Nat Rev Dis Primers. 2019;5(1):1-17. doi: 10.1038/s41572-019-0071-6.

15. Kasuki L., Rocha P.D.S., Lamback E.B., Gadelha M.R. Determinants of morbidities and mortality in acromegaly. Arch Endocrinol Metab. 2019;63(6):630-637. doi: 10.20945/2359-3997000000193.

16. Giustina A., Barkan A., Beckers A., Biermasz N., Biller B.M.K., Boguszewski C. et al. A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update. J Clin Endocrinol Metab. 2020;105(4):e937-e946. doi: 10.1210/clinem/dgz096.

17. Esposito D., Ragnarsson O., Johannsson G., Olsson D.S. Prolonged diagnostic delay in acromegaly is associated with increased morbidity and mortality. Eur J Endocrinol. 2020;182(6):523-531. doi: 10.1530/EJE-20-0019.

18. Gadelha M.R., Kasuki L., Lim D.S.T., Fleseriu M. Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update. Endocr Rev. 2019;40(1):268-332. doi: 10.1210/er.2018-00115.

19. Brue T., Castinetti F. The risks of overlooking the diagnosis of secreting pituitary adenomas. Orphanet J Rare Dis. 2016;11(1):1-17. doi: 10.1186/s13023-016-0516-x.

20. Belaya Z.E., Golounina O.O., Rozhinskaya L.Y., Melnichenko G.A., Isakov MA., Lutsenko A.S. et al. Epidemiology, clinical manifestations and efficiency of different methods of treatment of acromegaly according to the United Russian Registry of Patients with Pituitary Tumors. Problemy Ehndokrinologii = Problems of Endocrinology. 2020;66(1):93-103. (In Russ.) doi: 10.14341/probl10333.

21. Maione L., Chanson P. National acromegaly registries. Best Pract Res Clin Endocrinol Metab. 2019;33(2):101264. doi: 10.1016/j.beem.2019.02.001.

22. Buchfelder M., Feulner J. Chapter Six - Neurosurgical Treatment of Acromegaly. Prog Mol Biol Transl Sci. 2016;138:115-139. doi: 10.1016/bs.pmbts.2015.11.002.

23. Buchfelder M., Schlaffer S.M. The surgical treatment of acromegaly. Pituitary. 2017;(1):76-83. doi: 10.1007/s11102-016-0765-7.

24. Araujo-Castro M., Pascual-Corrales E., Martfnez-Vaello V., Baonza Saiz G., Quinones de Silva J., Acitores Cancela A. et al. Predictive model of surgical remission in acromegaly: age, presurgical GH levels and Knosp grade as the best predictors of surgical remission. J Endocrinol Invest. 2021;44(1):183-193. doi: 10.1007/s40618-020-01296-4.

25. Kim J.H., Hur K.Y., Lee J.H., Lee J.H., Se Y.B., Kim H.I. et al. Outcome of Endoscopic Transsphenoidal Surgery for Acromegaly. World Neurosurg. 2017;104:272-278. doi: 10.1016/j.wneu.2017.04.141.

26. Fatemi N., Dusick J.R., de Paiva Neto M.A., Kelly D.F. The endonasal microscopic approach for pituitary adenomas and other parasellar tumors: a 10-year experience. Neurosurgery. 2008;63(4 Suppl.):244-256. doi: 10.1227/01.NEU.0000327025.03975.BA.

27. Briceno V., Zaidi H.A., Doucette J.A., Onomichi K.B., Alreshidi A., Mekary R.A., Smith T.R. Efficacy of transsphenoidal surgery in achieving biochemical cure of growth hormone-secreting pituitary adenomas among patients with cavernous sinus invasion: a systematic review and meta-analysis. Neurol Res. 2017;39(5):387-398. doi: 10.1080/01616412.2017.1296653.

28. Hazer D.B., I§ik S., Berker D., Guler S., Gurlek A., Yucel T., Berker M. Treatment of acromegaly by endoscopic transsphenoidal surgery: surgical experience in 214 cases and cure rates according to current consensus criteria. J Neurosurg. 2013;119(6):1467-1477. doi: 10.3171/2013.8.JNS13224.

29. Li D., Johans S., Martin B., Cobb A., Kim M., Germanwala A.V. Transsphenoidal Resection of Pituitary Tumors in the United States, 2009 to 2011: Effects of Hospital Volume on Postoperative Complications. J Neurol Surg B Skull Base. 2021;82(2):175-181. doi: 10.1055/s-0040-1701218.

30. Bolfi F., Neves A.F., Boguszewski C.L., Nunes-Nogueira V.S. Mortality in acromegaly decreased in the last decade: a systematic review and meta-analy-sis. Eur J Endocrinol. 2018;179(1):59-71. doi: 10.1530/EJE-18-0255.

31. Postma M.R., Wolters T.L.C., van den Berg G., van Herwaarden A.E., Muller Kobold A.C., Sluiter W.J. et al. Postoperative use of somatostatin analogs and mortality in patients with acromegaly. Eur J Endocrinol. 2019;180(1):1-9. doi: 10.1530/EJE-18-0166.

32. Starostina E.G., Bobrov A.E., Alexandrova M.M. Types and prevalence of mental disorders in patients with acromegaly. RMGH = RMJ. 2017;(1):18-23. (In Russ.) Available at: https://www.rmj.ru/articles/endokrinologiya/Vidy_i_rasprostranennosty_psihicheskih_rasstroystv_u_bolynyh_akromegaliey/#ixzz6sNY9GFns.

33. Fernandez-Lazaro C.I., Garda-GonzalezJ.M., Adams D.P., Fernandez-Lazaro D., Mielgo-Ayuso J., Caballero-Garcia A. et al. Adherence to treatment and related factors among patients with chronic conditions in primary care: a cross-sectional study. BMC Fam Pract. 2019;20(1):132. doi: 10.1186/s12875-019-1019-3.

34. Morisky D.E., Green L.W., Levine D.M. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24: 67-74. doi: 10.1097/00005650-198601000-00007.

35. Crespo I., Valassi E., Webb S.M. Update on quality of life in patients with acromegaly. Pituitary. 2017;20(1):185-188. doi: 10.1007/s11102-016-0761-y.

36. Webb S.M., Badia X. Quality of Life in Acromegaly. Neuroendocrinology. 2016;103(1):106-111. doi: 10.1159/000375451.

37. Gatto F., Campana C., Cocchiara F., Corica G., Albertelli M., Boschetti M. et al. Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly. Rev Endocr Metab Disord. 2019;20(3):365-381. doi: 10.1007/s11154-019-09506-y.

38. Giustina A., Chanson P., Kleinberg D., Bronstein M.D., Clemmons D.R., Klibanski A. et al. Expert consensus document: A consensus on the medical treatment of acromegaly. Nat Rev Endocrinol. 2014;10(4):243-248. doi: 10.1038/nrendo.2014.21.

39. Gomes-Porras M., Cardenas-Salas J., Alvarez-Escola C. Somatostatin Analogs in Clinical Practice: a Review. Int J Mol Sci. 2020;21(5):1682. doi: 10.3390/ijms21051682.

40. Bevan J.S. Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab. 2005;90(3):1856-1863. doi: 10.1210/jc.2004-1093.

41. Caron PJ., Bevan J.S., Petersenn S., Flanagan D., Tabarin A., Prevost G. et al. Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. J Clin Endocrinol Metab. 2014;99(4):1282-1290. doi: 10.1210/jc.2013-3318.

42. Dogadin S.A., Dudina M.A., Lobyntseva L.A. The treatment of acromegaly with long-acting octreotide: the effective control of disease activity and decrease of the tumour volume. Problemy Ehndokrinologii = Problems of Endocrinology. 2012;58(4):3-7. (In Russ.) doi: 10.14341/probl20125843-7.

43. Dreval A.V., Ilovayskaya I.A., Pokramovich Yu.G., Stashuk G.A., Abramenko A.S., Tishenina R.S. Change of volume somatotropinpma in patients received Octreotid-depot. Problemy Ehndokrinologii = Problems of Endocrinology. 2014;60(4):12-16. (In Russ.) doi: 10.14341/probl201460412-16.

44. Anciferov M.B., Pronin V.S., Alekseeva T.M., Dorofeeva L.G. Experience of maintenance of moscow register of patients with acromegaly: potentials for the solution of various therapeutic problems. Farmateka. 2013;(16):42-47. (In Russ.) Available at: https://pharmateca.ru/ru/archive/article/12676.

45. Bova E., Tkachenko E., Zhitin P. Acromegaly: diagnostic and treatment in growth in the Rostov Region. Glavnyy vrach Yuga Rossii = Chief Physician of the South of Russia. 2019;1(65):27-30. (In Russ.).

46. Shagun O.V. Khamnueva LYu.,Andreeva L.S., Zudaev V.P. The analysis of the register of patients with acromegaly in Irkutsk region. Sibirskiy medit-sinskiy zhurnal (g. Tomsk) = Siberian Medicine Journal (Tomsk). 2011;26(4-2): 53-56. (In Russ.) Available at: https://elibrary.ru/item.asp?id=17364926.

47. Ilovaiskaya I.A., Molivosbvova N.N., Marova Y.I., Dzeranova L.K., Arapova S.D., Astafyeva L.I. et al. Drug treatment for acromegaly: results of long-term use of Sandostatin LAR. Problemy Ehndokrinologii = Problems of Endocrinology. 2006;52(4):34-38. (In Russ.) doi: 10.14341/probl200652434-38.

48. Anciferov M.B., Pronin E.V., Alekseeva T.M., Pronin V.S. Predictors of the effectiveness of drug therapy of acromegaly (according to the Moscow register). Farmateka. 2020;27(4):50-56. (In Russ.) doi: 10.18565/pharmateca.2020.4.50-56.

49. Murray R.D., Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab. 2008;93(8):2957-2968. doi: 10.1210/jc.2008-0027.

50. Freda P.U., Katznelson L., van der Lely A.J., Reyes C.M., Zhao S., Rabinowitz D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2005;90(8):4465-4473. doi: 10.1210/jc.2005-0260.

51. Gurel M.H., Han Y., Stevens A.L., Furtado A., Cox D. Treatment adherence and persistence with long-acting somatostatin analog therapy for the treatment of acromegaly: a retrospective analysis. BMC Pharmacol Toxicol. 2017;18(1):22. doi: 10.1186/s40360-017-0124-y.

52. Adelman D., Truong Thanh X.M., Feuilly M., Houchard A., Cella D. Evaluation of Nurse Preferences Between the Lanreotide Autogel New Syringe and the Octreotide Long-Acting Release Syringe: An International Simulated-Use Study (PRESTO). Adv Ther. 2020;37(4):1608-1619. doi: 10.1007/s12325-020-01255-8.

53. Bevan J.S., Newell-Price J., Wass J.A., Atkin S.L., Bouloux P.M., Chapman J. et al. Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective. Clin Endocrinol (Oxf). 2008;68(3):343-349. doi: 10.1111/j.1365-2265.2007.03044.x.

54. Salvatori R., Nachtigall L.B., Cook D.M, Bonert V, Molitch M.E., Blethen S., Chang S. Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naive patients with acromegaly. Pituitary. 2010;13(2):115-122. doi: 10.1007/s11102-009-0207-x.

55. Witek P., Mucha S., Ruchala M. Patient satisfaction and preferences of lanre-otide Autogel treatment in acromegaly. Endokrynol Pol. 2016;67(6):572-579. doi: 10.5603/ep.2016.0066.

56. Salvatori R., Woodmansee W.W., Molitch M., Gordon M.B., Lomax K.G. Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registry. Pituitary. 2014;17(1):13-21. doi: 10.1007/s11102-012-0460-2.

57. Plunkett C., Barkan A.L. The care continuum in acromegaly: how patients, nurses, and physicians can collaborate for successful treatment experiences. Patient Prefer Adherence. 2015;9:1093-1099. doi: 10.2147/PPA.S84887.

58. Kunzler L.S., Naves L.A., Casulari L.A. Cognitive-behavioral therapy improves the quality of life of patients with acromegaly. Pituitary. 2018;21(3):323-333. doi: 10.1007/s11102-018-0887-1.

59. Conn V.S., Ruppar T.M. Medication adherence outcomes of 771 intervention trials: Systematic review and meta-analysis. Prev Med. 2017;99:269-276. doi: 10.1016/j.ypmed.2017.03.008.